Management of hypertension in patients with diabetes mellitus. Defining the role of Lisinopril

Disease Management and Health Outcomes

Volumn 7, Issue 5, 2000, Pages 267-288

  Jarvis, Blair ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FELODIPINE; ISRADIPINE; LISINOPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT;

COMORBIDITY; COUGHING; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DRUG MECHANISM; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; VERTIGO; WEIGHT GAIN;

EID: 0034043596     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200007050-00004     Document Type: Review

References (201)

1. 1. AstraZeneca. Zestril prescribing information [on line]. [Accessed 2000, Mar 10]. AstraZeneca Ltd. Available from: URL: http://www.zestrilinfo.com/info/info.htm
2. 2. Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988 Jun; 35: 646-69
3. 3. Goa KL, Balfour JA, Zuanetti G. Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996 Oct; 52: 564-88
4. 4. Langtry HD, Markham A. Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997 Feb; 10: 131-66
5. 5. Goa KL, Haria M, Wilde MI. Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997 Jun; 53: 1081-105
6. 6. Simpson K, Jarvis B, Lisinopril: a review of its use in congestive heart failure. Drugs. In press
7. 7. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Med 1998; 15: 297-303
8. 8. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes. Hypertension 1994; 23: 145-58
9. 9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000 Jan; 23 Suppl. 1: S4-S19
10. 10. Alberti KGMM, Zimmet PZ, for the WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-53
11. 11. The DECODE-study group on behalf of the European Diabetes Epidemiology Group. Is fasting plasma glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-54
12. 12. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998 Aug 8; 317: 371-5
13. 13. Resnick HE, Harris MI, Brock DB, et al. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000 Feb; 23 (2): 176-80
14. 14. Wareham NJ, O'Rahilly S. The changing classification and diagnosis of diabetes: new classification is based on pathogenesis, not insulin dependence. BMJ 1998 Aug 8; 317: 359-60
15. 15. The Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabetic Med 1999; 16: 918-25
16. 16. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999 Sep 7; 100: 1134-46
17. 17. Hayashi T, Tsumura K, Suematsu C, et al. High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men: The Osaka Health Survey. Diabetes Care 1999 Oct; 22: 1683-7
18. 18. Epstein M. Diabetes and hypertension: the bad companions. J Hypertens 1997; 15 Suppl. 2: S55-62
19. 19. Tanaka Y, Onuma T, Atsumi Y, et al. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 1998 Jan; 21 (1): 116-20
20. 20. Bilo HJG, Gans ROB. Hypertensive patients and diabetes: a high-risk population. J Cardiovasc Pharmacol 1998; 32 Suppl. 2: S1-8
21. 21. Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease - chicken, egg, or neither? Diabetologia 1984 Feb; 26 (2): 99-102
22. 22. Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 1995 Apr; 44: 369-74
23. 23. Hsueh WA, Law R. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998; 105 Suppl. 1A: 4S-14S
24. 24. Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. Am J Med 1998; 105 Suppl. 1A: 77S-82S
25. 25. Nathan DM, Meigs J, Singer DE. The epidemiology of cardio vascular disease in type 2 diabetes mellitus: how sweet it is..or is it? Lancet 1997 July; 350 Suppl. 1: S14-9
26. 26. Sowers JR, Lester MA. Diabetes and Cardiovascular Disease. Diabetes Care 1999 Apr; 22 Suppl. 3: C14-20
27. 27. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997 July; 350 Suppl. 1: S120-3
28. 28. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000 Jan 12; 283 (2): 221-8
29. 29. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997 Jul; 350 Suppl. 1: S19-113
30. 30. Tooke JE, Goh KL. Vascular function in Type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheliopathy. Diabetic Med 1999 Sep; 16: 710-5
31. 31. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996 Feb 8; 334 (6): 374-81
32. 32. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): II. increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; II: 319-25
33. 33. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000 Jan 25; 101: 329-35
34. 34. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999 Nov; 34 (5): 795-808
35. 35. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996 Feb; 27 (2): 167-94
36. 36. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999 Dec 23-30; 402 (6764): 880-3
37. 37. Kennon B, Petrie JR, Small M, et al. Angiotensin-converting enzyme gene and diabetes mellitus. Diabetic Med 1999; 16: 448-58
38. 38. Gambaro G, Anglani F, D'Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet 2000 Jan 22; 355 (9200): 308-11
39. 39. Marre M, Bernadet P, Gallois Y, et al. Relationships between angiotensin 1 converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994 Mar; 43 (3): 384-8
40. 40. Bengtsson K, Orho-Melander M, Lindblad U, et al. Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension and diabetes project. J Hypertens 1999 Nov; 17 (11): 1569-75
41. 41. Estacio RO, Jeffers BW, Havranek EP, et al. Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. Am J Hypertens 1999; 12 (6): 637-42
42. 42. Oue T, Namba M, Nakajima H, et al. Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients - a 10 year follow-up study. Diabetes Res Clin Pract 1999 Oct; 46 (1): 47-55
43. 43. Yoshida H, Kuriyama S, Atsumi Y, et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996; 50: 657-64
44. 44. Powrie JK, Watts GF, Ingham JN, et al. Role of glycaemic control in development of microalbuminuria in patients with insulin dependent diabetes. BMJ 1994 Dec 17; 309: 1608-12
45. 45. Fujisawa T, Ikegami H, Shen G-Q, et al. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995 Jul; 18 (7): 983-5
46. 46. Schmidt S, Schöne N, Ritz E, et al. Association of ACE gene polymorphism and diabetic nephropathy. Kidney Int 1995; 47: 1176-81
47. 47. Nakajima S, Baba T, Yajima Y, et al. Is ACE gene polymorphism a useful marker for diabetic albuminuria in Japanese NIDDM patients? Diabetes Care 1996 Dec; 19 (12): 1420-2
48. 48. Tarnow L, Cambien F, Rossing P, et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995 May; 44: 489-94
49. 49. Parving H-H, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996 Sep 7; 313: 591-4
50. 50. Huang X-H, Rantalaiho V, Wirta O, et al. Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM. Hum Genet 1998; 102: 372-8
51. 51. Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41: 745-59
52. 52. Tarnow L, Rossing P, Nielsen FS, et al. Cardiovascular morbidity and early mortality cluster in parents of type I diabetic patients with diabetic nephropathy. Diabetes Care 2000 Jan; 23 (1): 30-3
53. 53. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53
54. 54. Kunz R, Bork JP, Fritsche L, et al. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9: 1653-63
55. 55. World Health Organization. The World Health Report 1999 -making adifference [on line]. [Accessed 16 Dec, 1999] World Health Organization. Available from: URL: http://www.oms. ch.whr/1999/en/pdf/whr99.puf
56. 56. Amos AF, McCarty DJ, Zimmet P, et al. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997; 14 Suppl. 5: S7-85
57. 57. Eastman RC, Keen H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet 1997 Jul; 350 Suppl. 1: S129-32
58. 58. Kaseta JR, Skafar DF, Ram JL, et al. Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab 1999; 84 (6): 1835-8
59. 59. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998 Mar 23; 158: 617-21
60. 60. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo study. JAMA 1991 Feb 6; 265 (5): 627-31
61. 61. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987 Aug; 114 (2): 413-9
62. 62. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993 Feb; 16 (2): 434-44
63. 63. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-17
64. 64. Jager A, Kostense PJ, Nijpels G, et al. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia 1998 Jun; 41: 694-700
65. 65. Gall M-A, Rossing P, Skøtt P, et al. Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 655-61
66. 66. Collado-Mesa F, Colhoun HM, Stevens LK, et al. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabetic Med 1999 Jan; 16: 41-8
67. 67. Wang S-L, Head J, Stevens L, et al. Excess mortality and its relation to hypertension and proteinuria in diabetic patients: The World Health Organization Multinational Study of Vascular Disease in Diabetes. Diabetes Care 1996 Apr; 19 (4): 305-12
68. 68. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998 Mar 14; 316: 823-8
69. 69. Marshall SM. Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. Diabetic Med 1999 May; 16: 358-72
70. 70. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997 Jul 14; 157: 1413-8
71. 71. Donnelly R, Molyneaux L, McGill M, et al. Detection and treatment of hypertension in patients with non-insulin-dependent diabetes mellitus: does the 'rule of halves' apply to a diabetic population? Diabetes Res Clin Pract 1997 Jul; 37: 35-40
72. 72. Bloomgarden ZT. The European Association for the Study of Diabetes annual meeting, 1998: The UK Prospective Diabetes Study and other topics in type 2 diabetes. Diabetes Care 1999 Jun; 22 (6): 989-95
73. 73. O'Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998 Jul; 21 (7): 1122-8
74. 74. Brown JB, Nichols GA, Glauber HS, et al. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 1999 Jul; 22 (7): 1116-24
75. 75. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998 Sep 12; 317: 720-6
76. 76. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997 May; 20 (5): 735-44
77. 77. Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293-301
78. 78. Barnett AH, Law VA, Lecomte PP, et al. Economic evaluation of angiotensin converting enzyme inhibitors in the prevention of diabetic nephropathy [abstract no. 1036]. Diabetologia 1999 Aug; 42 Suppl. 1: A 274
79. 79. Clark WF, Churchill DN, Forwell L, et al. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Can Med Assoc J 2000 Jan 25; 162 (2): 195-8
80. 80. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999 Nov 2; 131 (9): 660-7
81. 81. Kiberd BA, Jindal KK. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 1998 Jan; 31 (1): 49-54
82. 82. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for Type I diabetes: a Swiss perspective. Diabetologia 2000; 43: 13-26
83. 83. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000 Mar; 23 (3): 390-404
84. 84. Donnelly R, Emslie-Smith AM, Gardner ID, et al. ABC of arterial and venous disease: vascular complications of diabetes. BMJ 2000 Apr 15; 320: 1062-6
85. 85. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14): 977-86
86. 86. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000 Feb 10; 342 (6): 381-9
87. 87. Gaede P, Vedel P, Parving H-H, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999 Feb 20; 353: 617-22
88. 88. Ohkuho Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17
89. 89. Feld S, Hellman R, Dickey RA, et al. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management-1999 update. Endocrine Practice 2000 Jan/Feb; 6 (1): (in press) [Available online at: http://aace.com/]
90. 90. Herman WH. Clinical evidence: glycaemic control in diabetes. BMJ 1999 Jul 10; 319: 104-6
91. 91. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S27-31
92. 92. American Diabetes Association. Aspirin therapy in diabetes [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S61-2
93. 93. American Diabetes Association. Management of dyslipidemia in adults with diabetes [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S57-60
94. 94. European Diabetes Policy Group 1998. A desktop guide to Type I (insulin-dependent) diabetes mellitus. Diabetic Med 1999; 16: 253-66
95. 95. European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellilus. Diabetic Med 1999 Sep; 16: 716-30
96. 96. Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999 Sep; 13: 569-92
97. 97. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999 Sep 4; 319: 630-5
98. 98. Guidelines Subcommittee of the World Health Organisation -International Society of Hypertension (WHO - ISH). 1999 World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17 (2): 151-83
99. 99. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
100. 100. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S32-42
101. 101. American Diabetes Association. Diabetes mellitus and exercise [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S50-4
102. 102. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S43-46
103. 103. Carretero OA, Oparil S. Essential hypertension. Part II: treatment. Circulation 2000 Feb 1; 101: 446-53
104. 104. Jacobson AM. The psychological care of patients with insulin-dependent diabetes mellitus. N Engl J Med 1996 May 9; 334 (19): 1249-53
105. 105. American Diabetes Association. Smoking and diabetes [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S63-64
106. 106. Eriksson J, Lindström J, Valle T, et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland: study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999; 42: 793-801
107. 107. Dyson PA, Hammersley MS, Morris RJ, et al. The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997 Dec; 46 (12 Suppl. 1): 50-5
108. 108. Heilbronn LK, Noakes M, Clifton PM. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes. Diabetes Care 1999 Jun; 22 (6): 889-95
109. 109. Gumbiner B. Treating obesity in type 2 diabetes: calories, composition and control [editorial]. Diabetes Care 1999 Jun; 22 (6): 886-8
110. 110. Uchimoto S, Tsumura K, Hayashit T, et al. Impact of cigarette smoking on the incidence of Type 2 diabetes mellitus in middle-aged Japanese men: the Osaka Health Survey. Diabetic Med 1999; 16: 951-5
111. 111. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999 Nov; 22 (11): 1887-98
112. 112. Guzman CB, Sowers JR. Special considerations in the therapy of diabetic hypertension. Prog Cardiovasc Dis 1999 May/Jun; 41 (6): 461-70
113. 113. O'Driscoll G, Green D, Maiorana A, et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999 May; 33 (6): 1506-11
114. 114. Moan A, Os I, Hjermann I, et al. Hypertension therapy and risk of coronary heart disease: how do antihypertensives affect metabolic factors? Cardiology 1995; 86: 89-93
115. 115. Moan A, Hoieggen A, Seljeflot I, et al. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. Hypertension 1996 Sep; 14 (9): 1093-7
116. 116. Trenkwalder P, Dahl K, Lehtovirta M, et al. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press 1998 May; 7 (3): 170-5
117. 117. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med 1998 Apr 13; 158: 741-51
118. 118. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000 Mar 30; 342 (13): 905-12
119. 119. Majumdar SR. Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth. Cardiovasc Drugs Ther 1999; 13: 435-9
120. 120. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000 Mar 11; 320: 705-8
121. 121. Fisher CM. The ascendancy of diastolic blood pressure over systolic. Lancet 1985 Dec 14; 1: 1349-50
122. 122. Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999; 34: 386-7
123. 123. Lloyd-Jones D, Evans JC, Larson MG, et al. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension 1999 Sep; 34: 381-5
124. 124. Smulyan H, Safar ME. The diastolic blood pressure in systolic hypertension. Ann Intern Med 2000 Feb 1; 132 (3): 233-7
125. 125. Sever PS. Simple blood pressure guidelines for primary health care. J Hum Hypertens 1999; 13: 725-7
126. 126. Prisant LM, Moser M. Hypertension in the elderly: can we improve results of therapy? Arch Intern Med 2000 Feb 14; 160: 283-9
127. 127. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985 Jun 15; I (8442): 1349-54
128. 128. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996 Dec 18; 276 (23): 1886-92
129. 129. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991 Nov 23; 338 (8778): 1281-5
130. 130. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999 Mar 4; 340 (9): 677-84
131. 131. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335: 827-38
132. 132. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998 Sep 12; 317: 713-20
133. 133. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999 Feb 20; 353: 611-6
134. 134. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998 Mar 5; 338 (10): 645-51
135. 135. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (4): 597-603
136. 136. Sowers JR. Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). Am J Cardiol 1998 Nov 12; 82 Suppl. 9B: 15R-9R
137. 137. Califf RM, Granger CB. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET): more ammunition against surrogate end points. Diabetes Care 1998 Apr; 21 (4): 655-7
138. 138. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am J Cardiol 1998 Nov 12; 82 (9B): 9R-14R
139. 139. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999 Nov 4; 341 (19): 1447-57
140. 140. Pahor M, Tatti P. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapy [letter]. Am J Cardiol 1999 Mar 1; 83: 819-20
141. 141. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351: 1755-62
142. 142. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999 Nov 20; 354 (9192): 1751-6
143. 143. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 Jan 20; 342 (3): 145-53
144. 144. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 Jan 22; 355 (9200): 253-9
145. 145. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996 Feb; 12 (2): 127-37
146. 146. Fox C. Diabetes and hypertension: an era of clarity or confusion? J Hum Hypertens 1999 Apr; 13 Suppl. 2: S9-17
147. 147. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
148. 148. Hypertension in Diabetes Study Group. Hypertension in diabetes study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996; 39: 1554-61
149. 149. Salvetti A, Mattei P, Sudano I. Renal protection and antihypertensive drugs: current status. Drugs 1999 May; 57: 665-93
150. 150. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42: 263-85
151. 151. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999 Oct 7; 341 (15): 1127-33
152. 152. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998 Jul 18; 352: 213-9
153. 153. Ismail N, Becker B, Strzelczyk P, et al. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-28
154. 154. American Diabetes Association. Diabetic Nephropathy [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S69-S72
155. 155. Tomson CRV. Recent Advances: Nephrology. BMJ 2000 Jan 8; 320: 98-101
156. 156. Sawicki PT. Do ACE inhibitors offer specific benefits in the antihypertensive treatment of diabetic patients? 17 years of unfulfilled promises. Diabetologia 1998; 41: 598-602
157. 157. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993 Nov 11; 329 (20): 1456-62
158. 158. Wilmer AW, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999 Aug; 34 (2): 308-14
159. 159. Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999 Nov; 34 (5): 809-17
160. 160. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993 Apr 15; 118 (8): 577-81
161. 161. Trocha AK, Schmidtke C, Didjurgeit U, et al. Effects of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study. Hypertension 1999 Oct; 17 (10): 1497-503
162. 162. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999 Jul; 22 (7): 1125-36
163. 163. Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997 Dec 16; 96 (12): 4239-45
164. 164. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 1-7
165. 165. AstraZencca. Zestril prescribing summary (rev 12/98) [on line]. [Accessed 18 April, 2000]. Zeneca Pharmaceuticals USA. Available from: URL: http://167.2.16.105/pi/pibs_zestril.htm
166. 166. AstraZeneca. Zestoretic prescribing summary (rev 1/98) [on line]. [Accessed 18 April, Dec 1999]. Zeneca Pharmaceuticals USA. Available from: URL: http://167.2.16.105/pi/ pibs_zestoretic.htm
167. 167. British National Formulary. No. 38. London: The Pharmaceutical Press, Sep 1999
168. 168. AstraZeneca. Zestril. Summary of Product Characteristics.
169. 169. AstraZeneca. Zestoretic. Summary of Product Characteristics.
170. 170. Valimaki MJ. Lisinopril in the treatment of diabetic patients with moderate essential hypertension [abstract]. Diabetes 1991 May; 40 Suppl. 1: 371
171. 171. Corradi L, Zoppi A, Tettamanti F, et al. Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus. J Hypertens 1993 Dec; 11 Suppl. 5: S190-1
172. 172. Gonera RK, van der Heul C, van Boven WPL. Effects of lisinopril and metoprolol on microalbuminuria in hypertensive patients with non-insulin-dependent-diabetes-mellitus [abstract]. Nephrol Dial Transplant 1994; 9 (7): 953-4
173. 173. Rohr G, for the Lisinopril/Metoprolol Study Group. Evaluation of the antihypertensive effect of lisinopril compared to metoprolol in patients with diabetes mellitus (type II) and mild to moderate hypertension. In: Keane WF, editor. A focus on the clinical effects of a long acting ACE inhibitor/hypertension. New York: Raven Press, 1990: 83-9
174. 174. Agardh C-D, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996 Mar; 10: 185-92
175. 175. Friedman N, Anzalone D, Wilson A, et al. Efficacy of lisinopril and nifedipine GITS in hypertension associated with non-insulin dependent diabetes [abstract]. Diabetes 1994; 43 Suppl. 1: 59
176. 176. Grandinetti O, Cosentino G, Feraco E. Lisinopril versus ramipril: efficacy and safety in elderly hypertensives with non-insulin dependent diabetes mellitus [abstract]. J Hypertens 1992 Jun; 10 Suppl. 4: 222
177. 177. Slataper R, Vicknair N, Sadler R. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993 Apr 26; 153: 973-80
178. 178. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992 Apr; 41: 912-9
179. 179. Crepaldi G, Carraro A, Brocco E, et al. Hypertension and noninsulin-dependent diabetes: a comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol 1995; 32: 203-8
180. 180. Holdaas H, Hartmann A, Lien MG, et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991 Feb; 229: 163-70
181. 181. Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997 Mar; 46: 481-7
182. 182. Nielsen FS, Rossing P, Gall M-A, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994 Sep; 43: 1108-13
183. 183. Nielsen FS, Rossing P, Gall M-A, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997 Jul; 46: 1182-8
184. 184. Bakris GL, Copley JB, Vicknair N. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996 Nov; 50: 1641-50
185. 185. O'Donnell MJ, Rowe BR, Lawson N, et al. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Hum Hypertens 1993 Aug; 7: 333-9
186. 186. Hasslacher C. Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J Diabetes Complications 1996 May-Jun; 10: 136-8
187. 187. Sorensen VB, Rossing P, Tarnow L, et al. Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. Clin Sci 1998 Dec; 95: 709-17
188. 188. Tarnow L, Sato A, Ali S, et al. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care 1999 Mar; 22: 491-4
189. 189. Kendall MJ. Conventional versus newer antihypertensive therapies - a draw [editorial]. Lancet 1999 Nov 20; 354 (9192): 1744-5
190. 190. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996 Apr: 9 (4): 342-60
191. 191. National Institutes of Health. NHLBI stops part of study-high blood pressure drug performs no better than standard treatment [on line]. [Accessed 2000, Mar 10] NIH News Release. Available from: URL: http://www.nih.gov/news/pr/mar2000/ nhlbi-08.htm
192. 192. Messerli FH. Implications of discontinuation of doxazosin arm of ALLHAT [commentary]. Lancet 2000 March 11; 355: 863-4
193. 193. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997 Jun 21; 349: 1787-92
194. 194. Bakris GL, Slataper R, Vicknair N. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994 Jan-Mar; 8: 2-6
195. 195. O'Donnell MJ, Rowe BR, Lawson N, et al. Placebo-controlled trial of lisinopril in normotensive patients with incipient nephropathy. J Hum Hypertens 1993 Aug; 7: 327-32
196. 196. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients witb incipient nephropathy and normal blood pressure. Diabetes Care 1998 Jan; 21 (1): 104-10
197. 197. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition on IDDM patients: findings from the EUCLID randomized controlled trial. Diabetes 1998 Sep; 47: 1507-11
198. 198. American Diabetes Association. Diabetic Retinopathy [Position Statement]. Diabetes Care 2000 Jan; 23 Suppl. 1: S73-76
199. 199. Chaturvedi N, Sjolie A-K, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive pacople with type 1 diabetes. Lancet 1998 Jan 3; 351: 28-31
200. 200. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch Intern Med 2000 Mar 13; 160: 685-93
201. 201. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy: British trial shows clear effects of treatment, especially blood pressure reduction. BMJ 1998 Sep 12; 317: 693-4